Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent seeks buyer

This article was originally published in The Gray Sheet

Executive Summary

Developer of the Custom NX biolimus A9-eluting stent with adjustable lengths and bioabsorbable polymer will pursue "strategic alternatives," including the possible sale of some or all of the firm's assets, Xtent says Jan. 23. The Menlo Park, Calif.-based company, which went public in 2007, plans to eliminate 112 of its 121 employees as of March 23. The firm cites "continued challenges" in the capital markets. Data on the stent, which has been evaluated in four human trials, was presented at TCT last October (1"The Gray Sheet" Oct. 20, 2008, p. 15)

You may also be interested in...



Xtent to liquidate

Developer of the Custom NX biolimus A9-eluting stent with adjustable lengths and bioabsorbable polymer plans to liquidate its assets and dissolve the company, subject to shareholder approval, Xtent announces May 15. The firm cited "continued challenges" in the capital markets when it eliminated most of its employees and began looking for buyers in January (1"The Gray Sheet" Feb. 2, 2009, In Brief)

TCT In Brief

PREPARE: St. Jude Medical's Proxis embolic protection device helps to resolve ST-segment elevation faster in patients with ST-elevated myocardial infarction, according to results of the 280-patient Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary PCI (PREPARE) trial, presented at the Transcatheter Cardiovascular Therapeutics scientific symposium on Oct. 15 by Karel Koch, University of Amsterdam. ST elevation refers to the electrocardiographic signal associated with impending infarction. In PREPARE, ST-elevation was immediately resolved in 66% of the patients randomized to percutaneous coronary intervention with embolic protection from Proxis, compared to 50% of patients treated with PCI without embolic protection. After 30 minutes, 75% of Proxis patients and 66% of control patients were out of ST-elevation. There were no complications with Proxis, which was 510(k)-cleared in 2003

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

Topics

UsernamePublicRestriction

Register

MT027067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel